Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
ID Serval
serval:BIB_8281472D9E9E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.
Périodique
Osteoporosis international
Auteur(s)
Biver E., Calmy A., Aubry-Rozier B., Birkhäuser M., Bischoff-Ferrari H.A., Ferrari S., Frey D., Kressig R.W., Lamy O., Lippuner K., Suhm N., Meier C.
ISSN
1433-2965 (Electronic)
ISSN-L
0937-941X
Statut éditorial
Publié
Date de publication
05/2019
Peer-reviewed
Oui
Volume
30
Numéro
5
Pages
1125-1135
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general population. Accordingly, age-related comorbidities, including osteoporosis, are increasing. Fracture risk is higher and increases approximately 10 years earlier in PLWH. Classical risk factors of bone fragility are highly prevalent in PLWH but factors specific for HIV infection itself and the type of antiretroviral therapy (ART) (triple combination antiretroviral therapy) regimen (especially tenofovir and protease inhibitors) also contribute to bone loss. The majority of bone loss occurs during virus activity and at initiation of ART (immune reconstitution) and is associated with an increase of bone resorption (upregulation RANKL). Recent data indicate that calcium and vitamin D supplements as ART initiation lower BMD loss. The reduction of tenofovir plasma concentrations with tenofovir alafenamide attenuates BMD loss but it remains unknown whether it will contribute to reduce fracture risk. Hence, special considerations for the management of bone fragility in PLWH are warranted. Based on the current state of epidemiology and pathophysiology of osteoporosis in PLWH, we provide the consensus of the Swiss Association against Osteoporosis on best practice for diagnosis, prevention, and management of osteoporosis in this population. Periodic assessment of fracture risk is indicated in all HIV patients and general preventive measures should be implemented. All postmenopausal women, men above 50 years of age, and patients with other clinical risk for fragility fractures qualify for BMD measurement. An algorithm clarifies when treatment with bisphosphonates and review of ART regimen in favour of more bone-friendly options are indicated.
Mots-clé
Bone fragility, Diagnosis, HIV, Management, Osteoporosis, Prevention
Pubmed
Web of science
Création de la notice
28/01/2019 9:11
Dernière modification de la notice
03/02/2020 15:13
Données d'usage